Results 201 to 210 of about 82,259 (373)

Cognitive outcome and cyclo-oxygenase-2 gene (−765 G/C) variation in the preterm infant

open access: green, 2006
David Harding   +4 more
openalex   +1 more source

Opioids in breast cancer: Between analgesia and modulation of tumour progression

open access: yesBritish Journal of Pharmacology, EarlyView.
Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun   +2 more
wiley   +1 more source

Rieske non-heme iron-dependent oxygenases catalyse diverse reactions in natural product biosynthesis.

open access: yesNatural product reports (Print), 2018
Christopher Perry   +3 more
semanticscholar   +1 more source

LCN2‐ACOD1 Signalling Affects the Post‐Injury Regeneration of Skeletal Muscle Through Mediating Ferroptosis

open access: yesCell Proliferation, EarlyView.
LCN2 mediates the suppression of C2C12 myoblast proliferation and myotube formation via erastin‐induced ferroptosis. Mechanistically, the LCN2‐ACOD1 axis regulates skeletal muscle growth via mitochondria‐associated ferroptosis, providing a theoretical basis for the prevention and therapy of muscle‐related diseases.
Xiaojing Hao   +12 more
wiley   +1 more source

Study and Modification of the Polycyclic Aromatic Hydrocarbon Degradation Gene Cluster in <i>Burkholderia</i> sp. FM-2. [PDF]

open access: yesMicroorganisms
Ma J   +8 more
europepmc   +1 more source

Insights Into Macrophage Ferroptosis: Implications for Atherosclerosis

open access: yesCell Proliferation, EarlyView.
Macrophage ferroptosis drives atherosclerosis by enhancing oxidative stress and inflammation, accelerating plaque progression and instability. Targeting macrophage ferroptosis presents a promising therapeutic strategy for atherosclerosis treatment.
Xiehui Chen, Xiangbo Liu, Changchun Zeng
wiley   +1 more source

Effects of sotagliflozin on markers of volume status and sodium handling in patients with type 1 diabetes: A biomarker analysis of the inTandem3 clinical trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Sotagliflozin, an inhibitor of sodium‐glucose co‐transporter (SGLT)‐1 and 2, reduces albuminuria, slows GFR decline, and may have diuretic and osmoregulatory effects. The effect of sotagliflozin added to insulin was assessed on markers of neurohormone activation and volume homeostasis in patients with type 1 diabetes (T1D).
Massimo Nardone   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy